BioCryst Pharmaceuticals completes acquisition of Astria Therapeutics, adds navenibart to HAE portfolio.

BioCryst Pharmaceuticals has completed its acquisition of Astria Therapeutics, enhancing its position as a leader in hereditary angioedema (HAE) treatment. The acquisition adds navenibart, a late-stage plasma kallikrein inhibitor, to BioCryst's HAE portfolio, offering the potential for every-three and every-six month dosing with high attack control. This positions navenibart to significantly improve treatment for HAE patients, complementing BioCryst's leading oral therapy ORLADEYO.